NJ Sues Insys Over Opioid Drug Push, Calls Conduct 'Evil'
Law360, New York (October 5, 2017, 6:48 PM EDT) -- New Jersey has slammed Insys Therapeutics Inc. with a civil lawsuit accusing it of trying to squeeze more profits from its opioid-fentanyl drug Subsys by marketing it for general chronic pain treatment despite its limited regulatory approval for cancer patients, Attorney General Christopher S. Porrino announced Thursday, calling the conduct "nothing short of evil."
Subsys only has U.S. Food and Drug Administration approval for the "narrow" purpose of treating breakthrough cancer pain in opioid-tolerant patients, according to the complaint. Yet the Chandler, Arizona-based pharmaceutical company directed its sales force to sell it to a broader patient population and at higher doses, the complaint said. ...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!